Press Releases Year None201920182017 November 12, 2019 SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights PDF Version October 24, 2019 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) PDF Version September 24, 2019 European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma PDF Version September 17, 2019 SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares PDF Version September 12, 2019 SpringWorks Therapeutics Announces Pricing Of Initial Public Offering PDF Version August 30, 2019 SpringWorks Therapeutics Appoints Alan Fuhrman to Its Board of Directors PDF Version August 29, 2019 SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors PDF Version August 15, 2019 SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer PDF Version July 30, 2019 European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1 PDF Version June 27, 2019 SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma PDF Version Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
November 12, 2019 SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights PDF Version
October 24, 2019 SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) PDF Version
September 24, 2019 European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma PDF Version
September 17, 2019 SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares PDF Version
August 29, 2019 SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors PDF Version
August 15, 2019 SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer PDF Version
July 30, 2019 European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1 PDF Version
June 27, 2019 SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma PDF Version
